While the XBI is up significantly, this is driven by under-owned or shorted stocks like Moderna. Meanwhile, the companies most specialist biotech funds actually own are "getting hammered," creating a disconnect between the index's performance and investors' actual portfolio returns.
A banker involved in the pulled $2B+ Aura IPO believes it has little read-through for the biotech sector. The issue was valuation sensitivity specific to the tech world's "go big or go home" mentality, not a fundamental lack of market appetite for new offerings.
Investors question Moderna's valuation, which approaches that of Sanofi, a company with a deep, established business. This highlights the market's extreme expectations for Moderna's pipeline, where much needs to succeed to justify the current stock price.
Despite a $1B upfront payment, some on the buy-side view the expanded Sanofi-Regeneron collaboration cynically. Described as an "old married couple coming to a stop," the deal is seen as a predictable extension of their Dupixent franchise rather than a bold new strategic move.
The AstraZeneca-Summit partnership is structured unconventionally. Rather than just supplying its drug for trials, AstraZeneca is making a $2B equity investment and funding R&D. This novel structure allows AZ to test multiple hypotheses while providing Summit with a crucial cash infusion.
AstraZeneca's $2 billion premium investment in Summit reveals a valuation gap. This occurred just months after Summit failed to raise $500 million from public markets, indicating corporate partners may have a higher risk tolerance or see strategic value that public investors don't pre-data.
A trio of significant deals in one week—Novo Nordisk, Merck, and Novartis all partnering with Chinese biotechs—underscores a major trend. Western pharmaceutical giants are now aggressively sourcing early-stage, preclinical assets from China to fuel their global R&D pipelines.
Emix Biopharma announced a follow-on financing concurrently with its spectacular pivotal trial data. This move immediately priced the stock, preventing a natural run-up on the good news and causing the stock to close down nearly 10%, frustrating existing investors.
Four-year data for Unicure's Huntington's gene therapy showed efficacy dropping from 75% disease slowing to 44%. This significant decline challenges the core "one-and-done" promise of gene therapy, raising critical questions about the long-term durability of the therapeutic effect.